Cognitive-Behavioral Stress Management Shows Mixed Results for HIV-Infected Patients
Summary and Comment Subscription required
In a randomized, controlled trial in Switzerland, cognitive-behavioral stress management was associated with improvements in quality of life and psychological well-being but not in clinical markers of HIV infection.
By Eric Strachan, PhD
May 12, 2008
Covering:
Berger S et al., AIDS 2008 Mar 30; 22:767
Non–AIDS-Defining Cancer in HIV-Infected Patients
Summary and Comment Subscription required
In a large urban cohort, non–AIDS-defining cancers have become more common than AIDS-defining ones.
Low CD4-Cell Counts — Not Just About OI Risk
In a cohort of patients receiving ART, lower CD4-cell counts increased the risk not only for AIDS-defining conditions but also for non–AIDS-defining disease.
Resistance: What You Don’t Know — Can It Hurt You?
Antiretroviral Rounds Free
Two experts weigh in on whether to switch regimens in a patient with evidence of triple-class resistance.
Does Viral-Load Testing Reduce Drug Resistance in Resource-Poor Settings?
Despite viral-load testing, high levels of drug resistance at first virologic failure were found in KwaZulu-Natal, South Africa.
By Renslow Sherer, MD
May 5, 2008
Covering:
Marconi VC et al., Clin Infect Dis 2008 May 15; 46:1589
Cefixime Tablets Available in the U.S. Again
Drug Watch Subscription required
Cefixime tablets (Suprax; 400 mg) are now available in the U.S. for the first time since 2002. Cefixime is the only CDC-recommended oral treatment for . . .
By ACC Editors
May 5, 2008
Covering:
Centers for Disease Control and Prevention (CDC)., MMWR Morb Mortal Wkly Rep 2008 Apr 25; 57:435
Caution Urged When Combining Lopinavir/Ritonavir and Rosuvastatin
Summary and Comment Subscription required
In a pharmacokinetic study involving 20 healthy volunteers, coadministration of lopinavir/ritonavir and rosuvastatin significantly increased rosuvastatin levels yet attenuated the LDL-lowering effect of the drug; one study participant experienced a grade 4 elevation in creatinine phosphokinase levels.
By Keith Henry, MD
April 28, 2008
Covering:
Kiser JJ et al., J Acquir Immune Defic Syndr 2008 Apr 15; 47:570
Both Fish Oil and Fibrates Reduce Triglyceride Levels
Summary and Comment Subscription required
Both fish oil and fenofibrate safely reduce elevated triglyceride levels in HIV-infected patients receiving ART.
By Keith Henry, MD
April 28, 2008
Covering:
Gerber JG et al., J Acquir Immune Defic Syndr 2008 Apr 1; 47:459
Rapid ART Scale-Up Needed in South Africa
Summary and Comment Subscription required
A mathematical model to estimate the effect of different antiretroviral scale-up scenarios suggests that rapid scale-up is critical if universal access is to be achieved during the next 5 years for all people in need of treatment.
By Salim S. Abdool Karim, MD, PhD
April 28, 2008
Covering:
Walensky RP et al., J Infect Dis 2008 May 1; 197:1324
Hirschhorn LR and Skolnik R., J Infect Dis 2008 May 1; 197:1223
Emergence of the K65R Mutation with NNRTI-Based Regimens
Summary and Comment Subscription required
In the Swiss HIV Cohort Study, emergence of the K65R mutation was significantly associated with tenofovir-containing regimens that were anchored by NNRTIs rather than by PIs.
By Manish Sagar, MD
April 18, 2008
Covering:
von Wyl V et al., Clin Infect Dis 2008 Apr 15; 46:1299
